Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 7/20 | 0.86 |
| ▸ | PPARG | P37231 | 7/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4884146 | 0.93 | SERPINE1 (1.00) | SERPINE1PPARGNR1I2PTGESPTGDR2 | |
| SCHEMBL4893854 | 0.90 | SERPINE1 (1.00) | SERPINE1PPARGNR1I2MAPK8 | |
| SCHEMBL4887004 | 0.83 | SERPINE1 (1.00) | SERPINE1PPARGNR1I2PTGDR2MAPK8 | |
| SCHEMBL5812761 | 0.82 | PTGES (0.65) | SERPINE1PPARGPTGESPPARA | |
| SCHEMBL4887483 | 0.81 | SERPINE1 (0.75) | SERPINE1PTGDR2SMN1; SMN2 | |
| SCHEMBL4892537 | 0.80 | SERPINE1 (1.00) | SERPINE1PPARGNR1I2PTGDR2MAPK8 | |
| SCHEMBL4982359 | 0.78 | SERPINE1 (0.92) | SERPINE1PPARGPTGESMAPK8 | |
| SCHEMBL4890974 | 0.77 | SERPINE1 (0.75) | SERPINE1NR1I2 | |
| SCHEMBL4980302 | 0.76 | SERPINE1 (1.00) | SERPINE1PPARGPTGES | |
| SCHEMBL4884301 | 0.73 | SERPINE1 (0.80) | SERPINE1MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319046-A1 | SUBSTITUTED SULFONAMIDE-INDOLES | WYETH (US) | 2008-12-25 | — | — | US | claimed |
| US-7442805-B2 | Substituted sulfonamide-indoles | WYETH (US) | 2008-10-28 | — | — | US | claimed |
| JP-2007506769-A | — | — | 2007-03-22 | — | — | JP | claimed |
| EP-1667969-A1 | SUBSTITUTED SULFONAMIDE-INDOLE-2-CARBOXYLIC ACID DERIVATIVES AS PAI-1 INHIBITORS | Wyeth (US) | 2006-06-14 | — | — | EP | claimed |
| US-20050096377-A1 | Substituted sulfonamide-indoles | WYETH (US) | 2005-05-05 | — | — | US | claimed |
| WO-2005030715-A1 | SUBSTITUTED SULFONAMIDE-INDOLE-2-CARBOXYLIC ACID DERIVATIVES AS PAI-1 INHIBITORS | WYETH (US) | 2005-04-07 | — | — | WO | claimed |
| US-20080319046-A1 | SUBSTITUTED SULFONAMIDE-INDOLES | WYETH (US) | 2008-12-25 | — | — | US | disclosed |
| US-7442805-B2 | Substituted sulfonamide-indoles | WYETH (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1667969-A1 | SUBSTITUTED SULFONAMIDE-INDOLE-2-CARBOXYLIC ACID DERIVATIVES AS PAI-1 INHIBITORS | Wyeth (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050096377-A1 | Substituted sulfonamide-indoles | WYETH (US) | 2005-05-05 | — | — | US | disclosed |
| WO-2005030715-A1 | SUBSTITUTED SULFONAMIDE-INDOLE-2-CARBOXYLIC ACID DERIVATIVES AS PAI-1 INHIBITORS | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319046-A1 | SUBSTITUTED SULFONAMIDE-INDOLES | STS, TPST2, IDO2 | SERPINE1 4706/4885PPARG 2610/4885NR1I2 2069/4885 |
| US-20050096377-A1 | Substituted sulfonamide-indoles | STS, TPST2, IDO2 | SERPINE1 4706/4885PPARG 2610/4885NR1I2 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.